Igor Kišš
About
Igor Kišš is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Igor Kišš has authored 97 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 36 papers in Cancer Research. Recurrent topics in Igor Kišš's work include Colorectal Cancer Treatments and Studies (18 papers), MicroRNA in disease regulation (16 papers) and Renal cell carcinoma treatment (14 papers). Igor Kišš is often cited by papers focused on Colorectal Cancer Treatments and Studies (18 papers), MicroRNA in disease regulation (16 papers) and Renal cell carcinoma treatment (14 papers). Igor Kišš collaborates with scholars based in Czechia, United Kingdom and Spain. Igor Kišš's co-authors include Ondřej Slabý, Marek Svoboda, Rostislav Vyzula, Lenka Radová, Petra Vychytilova‐Faltejskova, Zdeněk Kala, Kateřina Slabá, Vladimír Procházka, Milana Šachlová and Pavel Fabián and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Igor Kišš
81 papers receiving 1.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Igor Kišš Czechia | 23 | 910 | 874 | 636 | 398 | 213 | 97 | 1.7k | ||
| Renata A. Coudry Brazil | 20 | 587 0.6× | 438 0.5× | 624 1.0× | 557 1.4× | 192 0.9× | 37 | 1.4k | ||
| Axel Walther United Kingdom | 12 | 658 0.7× | 538 0.6× | 752 1.2× | 196 0.5× | 177 0.8× | 40 | 1.8k | ||
| John W. Moroney United States | 19 | 656 0.7× | 493 0.6× | 874 1.4× | 438 1.1× | 172 0.8× | 49 | 2.5k | ||
| Zachary R. Chalmers United States | 15 | 649 0.7× | 349 0.4× | 584 0.9× | 580 1.5× | 152 0.7× | 35 | 1.4k | ||
| Maja J.A. de Jonge Netherlands | 19 | 865 1.0× | 259 0.3× | 848 1.3× | 420 1.1× | 125 0.6× | 40 | 1.6k | ||
| Masataka Yoshimoto Japan | 26 | 630 0.7× | 734 0.8× | 810 1.3× | 258 0.6× | 236 1.1× | 84 | 1.8k | ||
| Aparna Kalyan United States | 26 | 802 0.9× | 523 0.6× | 1.1k 1.8× | 486 1.2× | 550 2.6× | 66 | 2.1k | ||
| Kim A. Reiss United States | 19 | 452 0.5× | 444 0.5× | 971 1.5× | 226 0.6× | 147 0.7× | 63 | 1.4k | ||
| Aglaya G. Iyevleva Russia | 22 | 689 0.8× | 482 0.6× | 588 0.9× | 473 1.2× | 90 0.4× | 78 | 1.5k | ||
| Stephan Krüger Germany | 19 | 483 0.5× | 354 0.4× | 932 1.5× | 317 0.8× | 133 0.6× | 65 | 1.6k |
Countries citing papers authored by Igor Kišš
Since
Specialization
Citations
This map shows the geographic impact of Igor Kišš's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Kišš with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Kišš more than expected).
Fields of papers citing papers by Igor Kišš
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Igor Kišš. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Kišš. The network helps show where Igor Kišš may publish in the future.
Co-authorship network of co-authors of Igor Kišš
This figure shows the co-authorship network connecting the top 25 collaborators of Igor Kišš. A scholar is included among the top collaborators of Igor Kišš based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor Kišš. Igor Kišš is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wainberg, Zev A., Davide Melisi, Teresa Macarulla, et al.. (2025). A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Future Oncology. 21(7). 765–774.
2.
Kišš, Igor, et al.. (2024). Electrochemical Detection of BRAF V600E Mutation in a Liquid Biopsy Format: LAMPing the Way to an Improved Diagnostics and Treatment. Advanced Materials Technologies. 10(7).
3.
Hussein, Maen, Gazala Khan, Sreenivasa R Chandana, et al.. (2024). NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.. Journal of Clinical Oncology. 42(16_suppl). 4136–4136.
4.
Selingerová, Iveta, Radek Lakomý, Alexandr Poprach, et al.. (2024). Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer. BMC Cancer. 24(1). 1590–1590.
5.
Selingerová, Iveta, Tomáš Kazda, Alexandr Poprach, et al.. (2024). Current real-world evidence on characteristics and treatment patterns of lung cancer in the single cancer center in the Czech Republic – data from Masaryk Memorial Cancer Institute registry in 2018–2022. Klinicka onkologie. 37(6). 433–444.
6.
Poprach, Alexandr, Igor Kišš, Michal Staník, et al.. (2023). Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma. Targeted Oncology. 18(6). 893–903.
7.
Fabián, Pavel, Iveta Selingerová, David Novák, et al.. (2023). FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer. Cancers. 15(6). 1901–1901.
8.
Hollá, Lýdie Izakovičová, et al.. (2020). Tooth agenesis: What do we know and is there a connection to cancer?. Clinical Genetics. 99(4). 493–502.
9.
Büchler, Tomáš, Igor Kišš, Ondřej Fiala, et al.. (2020). Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. Targeted Oncology. 15(2). 193–201.
10.
Novakova-Jiresova, Alena, Kateřina Kopečková, Ludmila Boublíková, et al.. (2020). <p>Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients</p>. Cancer Management and Research. Volume 12. 5365–5372.
11.
Poprach, Alexandr, Radek Lakomý, Michal Staník, et al.. (2019). Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. Urologic Oncology Seminars and Original Investigations. 37(4). 294.e1–294.e8.
12.
Büchler, Tomáš, Alexandr Poprach, Ondřej Fiala, et al.. (2018). Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. Cancer Management and Research. Volume 11. 359–368.
13.
Fiala, Ondřej, Veronika Veškrňová, Alexandr Poprach, et al.. (2018). Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. Targeted Oncology. 13(6). 735–743.
14.
Büchler, Tomáš, Alexandr Poprach, Zbyněk Bortlíček, et al.. (2017). Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. Clinical Genitourinary Cancer. 15(6). e1047–e1053.
15.
Lakomý, Radek, Alexandr Poprach, Zbyněk Bortlíček, et al.. (2017). Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC Cancer. 17(1). 880–880.
16.
Benson, Al B., Igor Kišš, John Bridgewater, et al.. (2016). BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer. Clinical Cancer Research. 22(20). 5058–5067.
17.
Poprach, Alexandr, Radek Lakomý, Zbyněk Bortlíček, et al.. (2016). Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs & Aging. 33(9). 655–663.
18.
Poprach, Alexandr, Zbyněk Bortlíček, Bohuslav Melichar, et al.. (2015). Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. European Journal of Cancer. 51(4). 507–513.
19.
Büchler, Tomáš, Zbyněk Bortlíček, Alexandr Poprach, et al.. (2014). Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. Urologic Oncology Seminars and Original Investigations. 32(5). 569–575.
20.
Elbl, Lubomı́r, et al.. (1998). Anthracyclines and the heart.. 7(4).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Renata A. Coudry Breakdown of academic impact, for papers by Axel Walther Breakdown of academic impact, for papers by John W. Moroney Breakdown of academic impact, for papers by Zachary R. Chalmers Breakdown of academic impact, for papers by Maja J.A. de Jonge Breakdown of academic impact, for papers by Masataka Yoshimoto Breakdown of academic impact, for papers by Aparna Kalyan Breakdown of academic impact, for papers by Kim A. Reiss Breakdown of academic impact, for papers by Aglaya G. Iyevleva Breakdown of academic impact, for papers by Stephan Krüger